Enhanced ERK activity extends ketamine's antidepressant effects by augmenting synaptic plasticity.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 40339008.
- Also identified by DOI 10.1126/science.abb6748 and PMC identifier 12714497.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Repeated ketamine treatment to maintain a rapid antidepressant effect can lead to side effects over time, highlighting an unmet clinical need for sustaining this drug's antidepressant action from a single administration. Ketamine-induced synaptic potentiation at CA3-CA1 synapses has been proposed to be a key synaptic substrate for antidepressant action. Here, we found that ketamine-induced CA3-CA1 synaptic potentiation could be augmented by transiently increasing extracellular signal-regulated kinase (ERK) activity through pharmacological inhibition of dual-specificity phosphatases 6 (DUSP6). The antidepressant-like behavioral effects of acute ketamine treatment were extended by DUSP6 inhibition for up to 2 months. The selective deletion of tropomyosin receptor kinase B (TrkB) in excitatory neurons abolished these DUSP6 inhibition-mediated synaptic and behavioral effects. These data suggest that ketamine's rapid antidepressant effects can be sustained by selectively targeting downstream intracellular signaling.
Medical subject headings
- Antidepressive Agents
- Dual Specificity Phosphatase 6
- Extracellular Signal-Regulated MAP Kinases
- Ketamine
- Neuronal Plasticity